CALR and dilated cardiomyopathy: In addition, the drug promotes increased expression of calreticulin and calsequestrin, which are involved in the sarcoplasmatic reticulum calcium pump and decrease cell contractility, which in vivo may lead to dilated cardiomyopathy in mice and humans as described previously [22,28,34,40].